Tailoring PSMA Radiopharmaceutical Selection for Personalized Prostate Cancer Theranostics

Personalizing PSMA radiopharmaceutical selection may enhance prostate cancer theranostics by matching agent properties to patient and tumor characteristics, according to an AJR review.

• Narrative review or perspective discussing optimal and personalized use of PSMA-targeted agents (Ga‑68, F‑18, Lu‑177) for imaging and therapy.
• Considers factors such as PSMA expression heterogeneity, pharmacokinetics, logistics, and intended clinical application.
• Specific data and sample size not reported in source; conclusions based on expert synthesis.

RadPigeon summaries are original and for information only. They are not clinical advice.